Data / Form D filings / Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc.: Form D filings
Orexigen Therapeutics, Inc., a pharmaceuticals company in La Jolla, CA, filed 3 Form D notices with the SEC between 2015 and 2017. The latest, on March 3, 2017, reports $49.6 million sold of a $49.6 million offering to 9 investors.
Find out what Orexigen Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3344 N. TORREY PINES CT., SUITE 200, La Jolla, CA, 92037
- Phone
- (858) 875-8600
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1382911
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 3, 2017 | New notice | $49,597,000 | $49,597,000 | $0 | 9 | Feb 23, 2017 | sec.gov |
| Mar 29, 2016 | New notice | $329,999,991 | $165,000,000 | $164,999,991 | 21 | Mar 21, 2016 | sec.gov |
| Sep 15, 2015 | New notice | $90,000,000 | $60,000,000 | $30,000,000 | 1 | Sep 10, 2015 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Deborah S Jorn | Director | |
| Thomas Lynch | Executive Officer | |
| Jason S Keyes | Executive Officer | |
| David J Endicott | Director | |
| Patrick J Mahaffy | Director | |
| Thomas Cannell | Executive Officer | |
| Louis C Bock | Director | |
| Peter K Honig | Director | |
| Peter Flynn | Executive Officer | |
| Brian H. Dovey | Director | |
| Michael Narachi | Executive Officer, Director | |
| Lota S Zoth | Director |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Feb 27, 2017 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Orexigen Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.